RAMSEY, N.J. and BOCA RATON, Fla., April 01, 2019 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company…Original Article
You may also like
FDA Approves Miudella (copper intrauterine system) for...
FDA Approves Ctexli (chenodiol) for Cerebrotendinous...
FDA Approves Merilog (insulin-aspart-szjj), a...
FDA Approves Xbryk (denosumab-dssb), a Biosimilar to...
FDA Approves Ospomyv (denosumab-dssb), a Biosimilar to...
FDA Approves Penmenvy (meningococcal groups A, B, C...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.